MX2021004134A - Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. - Google Patents

Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.

Info

Publication number
MX2021004134A
MX2021004134A MX2021004134A MX2021004134A MX2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A MX 2021004134 A MX2021004134 A MX 2021004134A
Authority
MX
Mexico
Prior art keywords
chaperone
benzoxazole
compounds useful
related compounds
formula
Prior art date
Application number
MX2021004134A
Other languages
English (en)
Spanish (es)
Inventor
Ana Maria Cuervo
Evripidis Gavathiotis
Original Assignee
Albert Einstein College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College Medicine filed Critical Albert Einstein College Medicine
Publication of MX2021004134A publication Critical patent/MX2021004134A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2021004134A 2018-10-10 2019-10-10 Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas. MX2021004134A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743920P 2018-10-10 2018-10-10
PCT/US2019/055493 WO2020077024A1 (en) 2018-10-10 2019-10-10 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators

Publications (1)

Publication Number Publication Date
MX2021004134A true MX2021004134A (es) 2021-07-16

Family

ID=70163886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004134A MX2021004134A (es) 2018-10-10 2019-10-10 Benzoxazol y compuestos relacionados útiles como moduladores de autofagia mediada por chaperonas.

Country Status (11)

Country Link
US (1) US12473266B2 (cg-RX-API-DMAC7.html)
EP (1) EP3863755A4 (cg-RX-API-DMAC7.html)
JP (1) JP7503850B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210082466A (cg-RX-API-DMAC7.html)
CN (1) CN113195084B (cg-RX-API-DMAC7.html)
AU (1) AU2019358074A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021006843A2 (cg-RX-API-DMAC7.html)
CA (1) CA3115297A1 (cg-RX-API-DMAC7.html)
IL (1) IL282069A (cg-RX-API-DMAC7.html)
MX (1) MX2021004134A (cg-RX-API-DMAC7.html)
WO (1) WO2020077024A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022015624A1 (en) * 2020-07-16 2022-01-20 Schrödinger, Inc. Substituted dihydropyrazinediones as modulators of the nmda receptor
JP2023551435A (ja) * 2020-11-20 2023-12-08 エフ. ホフマン-ラ ロシュ アーゲー B型肝炎ウイルス感染症の処置及び予防のためのn置換4-(1,3-アリールオキサゾロ-2-イル)フェニル化合物
WO2022155333A1 (en) * 2021-01-13 2022-07-21 Albert Einstein College Of Medicine Use of chaperone-mediated autophagy activators for treating or preventing blood cancers and myelodysplastic syndromes
EP4326267A4 (en) * 2021-04-21 2025-07-09 Albert Einstein College Medicine METHOD FOR INCREASING CHAPERONE-MEDIATED AUTOPHAGY BY STABILIZING THE INTERACTION BETWEEN THE RETINOIC ACID RECEPTOR ALPHA AND AN INHIBITOR
KR102778740B1 (ko) 2021-06-24 2025-03-07 주식회사 엘지화학 합성가스의 제조방법
CN114404421B (zh) * 2022-02-28 2023-04-28 同济大学 选择性自噬激活剂qx77在制备干预或治疗糖尿病视网膜病变的药物中的应用
WO2024225738A1 (ko) * 2023-04-25 2024-10-31 부산대학교 산학협력단 지방간질환 치료 또는 예방 목적의 fxr/ppar alpha 이중 작용 활성을 가지는 벤즈옥사졸 유도체 화합물

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH469802A (de) * 1966-01-07 1969-03-15 Ciba Geigy Verwendung von Benzoxazol-Derivaten als Scintillator-Substanzen
US5428052A (en) * 1984-09-19 1995-06-27 Centre Internationale De Recherches Dermatologiques (C.I.R.D.) Aromatic heterocyclic derivatives and their therapeutic and cosmetic use
ATE240942T1 (de) * 1995-11-17 2003-06-15 Merck & Co Inc Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
AU2002365892A1 (en) * 2001-11-30 2003-06-17 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
KR20040096601A (ko) 2002-02-21 2004-11-16 시바 스페셜티 케미칼스 홀딩 인크. 락탐계 안료 및 착색된 플라스틱 또는 중합체성 착색입자의 제조시 이의 용도
JP4903133B2 (ja) 2004-04-30 2012-03-28 ジェネンテック,インコーポレイティド ヘッジホッグシグナル伝達のキノキサリン阻害剤
UA91341C2 (ru) * 2004-07-15 2010-07-26 Амр Текнолоджи, Інк. Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
BRPI0707719A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto ou de um sal farmaceuticamente aceitÁvel do mesmo
GB0602768D0 (en) * 2006-02-10 2006-03-22 Vastox Plc Treatment of muscular dystrophy
RU2462458C2 (ru) * 2006-02-10 2012-09-27 Байомарин Ига Лимитед Лечение миодистрофии дюшена
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
AU2008285289A1 (en) 2007-08-03 2009-02-12 Biomarin Iga Limited Drug combinations for the treatment of Duchenne muscular dystrophy
MX2011002647A (es) 2008-09-23 2011-04-07 Wista Lab Ltd Ligandos para moleculas tau agregadas.
JP2011168515A (ja) 2010-02-17 2011-09-01 Kowa Co エリスロポエチン産生促進作用を有する2−アリールベンゾオキサゾール化合物
US9512092B2 (en) * 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
EP3187495A1 (en) * 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP3431472B1 (en) * 2016-03-17 2023-05-03 Checkmate Therapeutics Inc. Novel compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same
JP2018087173A (ja) 2016-11-29 2018-06-07 国立大学法人北海道大学 悪性脳腫瘍治療薬
US10308644B2 (en) 2016-12-22 2019-06-04 Incyte Corporation Heterocyclic compounds as immunomodulators
US10676467B2 (en) 2017-06-30 2020-06-09 Washington University Compositions for binding sphingosine-1-phosphate receptor 1 (S1P1), imaging of S1P1, and methods of use thereof

Also Published As

Publication number Publication date
AU2019358074A1 (en) 2021-05-06
JP2022504650A (ja) 2022-01-13
US12473266B2 (en) 2025-11-18
CA3115297A1 (en) 2020-04-16
IL282069A (en) 2021-05-31
JP7503850B2 (ja) 2024-06-21
KR20210082466A (ko) 2021-07-05
CN113195084A (zh) 2021-07-30
EP3863755A4 (en) 2022-08-03
BR112021006843A2 (pt) 2021-07-13
US20210387953A1 (en) 2021-12-16
CN113195084B (zh) 2024-04-09
EP3863755A1 (en) 2021-08-18
WO2020077024A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CL2021001461A1 (es) Moduladores de trex1
UY35818A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2017009614A2 (es) Compuestos bicíclicos de sulfonamida cetona
AR121047A1 (es) Inhibidores de map4k1
MX2017005668A (es) Nuevos compuestos de acido carboxilico utiles para inhibir la sintasa-1 de prostaglandina microsomal e2.
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CR20160478A (es) Composición de control de enfermedades de plantas y método para controlar enfermedades de plantas mediante su aplicación
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
UY36716A (es) Moduladores de receptores nucleares
MX2015012028A (es) Inhibidores de la ruta de quinurenina.
CL2021000844A1 (es) Compuestos de indolinona para uso como inhibidores de map4k1
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
DOP2019000193A (es) Nuevo compuesto heterocíclico, su método de preparación y composición farmacéutica que lo comprende
NI201700055A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CL2017002745A1 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
MX2021012305A (es) Derivados de heteroarilos biciclicos como inhibidores de ectonucleotido pirofosfatasa fosfodiesterasa 1.
EA201790496A1 (ru) Соединения 1-алкил-6-оксо-1,6-дигидропиридин-3-ила и применение в качестве модуляторов sgrm